CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 180 enrolled
Drug / intervention
CYD dengue vaccine serotypes (1, 2, 3, 4). +1 morebiological
Likely dose
CYD dengue vaccine serotypes (1, 2, 3, 4). 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00875524
NCT00875524Phase 2Completed
CompareCT.gov

Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam

Sanofi Pasteur, a Sanofi Company·interventional·Posted Apr 3, 2009·Updated Apr 5, 2022

In Brief

A Phase 2 clinical trial evaluating CYD dengue vaccine serotypes (1, 2, 3, 4). and Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide for Dengue Virus and 3 related conditions. Completed, enrolled 180 participants across 1 site.

Detailed Summary

This trial evaluated the use of a tetravalent vaccine against dengue. Primary objectives: * To describe the humoral immune response to dengue before and after each vaccination with tetravalent dengue vaccine in adults, adolescents, and children. * To evaluate the safety of each vaccination with tetravalent dengue vaccine in the 4 age cohorts. * To evaluate the persistence of antibodies against dengue during 5 years after the first vaccination with tetravalent dengue vaccine in the 4 age cohorts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Disease
CountriesVietnam
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 3, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 17.2 years ago

Interventions

CYD dengue vaccine serotypes (1, 2, 3, 4).biological

0.5 mL, Subcutaneous

Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharidebiological

Each at 0.5 mL, Subcutaneous, respectively